All In Biotech

Drug Trial Radar · NCT07792954

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-WEEKLY PF-08653944 IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 24, 2026

Primary completion

Mar 14, 2028

Study completion May 23, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions. The purpose of this study is to learn whether berobenatide is safe and effective for adults in China who have overweight or obesity. Researchers will compare berobenatide with a placebo, which looks like the study treatment but does not contain active medicine. People may be able to participate if they are adults with obesity or if they have overweight together with certain weight-related health conditions. Some participants may also have type 2 diabetes. Specific eligibility requirements will be reviewed by the study doctor before enrollment. Participants will be randomly assigned to receive either berobenatide or placebo. The study treatment will be administered according to the study protocol, and participants will be monitored throughout the study to assess changes in body weight and overall health, as well as any side effects that may occur. During participation, participants will attend study visits and complete study-related assessments. Researchers will collect information about participants' health, body weight, and safety throughout the study. Details about the number of visits, study duration, and study procedures will be explained by the study team before participation. The information learned from this study may help researchers better understand whether berobenatide could be a treatment option for adults living with overweight or obesity.

Conditions

  • Obesity
  • Overweight

Interventions

  • BerobenatideDrug

    Solution for injection

  • PlaceboOther

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body Weight at Week 48Time frame: Baseline to Week 48

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University General Hospital

    Tianjin, China · Recruiting

  • The Second People's Hospital of Hefei

    Hefei, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Pinggu Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing People's Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, China · Recruiting

  • Harrison International Peace Hospital

    Hengshui, Hebei, China · Recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • The Fourth Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Recruiting

  • Luoyang First People's Hospital

    Luoyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, Henan, China · Recruiting

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Shiyan Taihe Hospital

    Shiyan, Hubei, China · Not yet recruiting

  • Wuhan Third Hospital

    Wuhan, Hubei, China · Recruiting

  • Changzhou Second People's Hospital

    Changzhou, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • Nanjing First Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China · Recruiting

  • The Second Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • The First Affiliated Hospital of Xi'an Medical University

    Xi'an, Shaanxi, China · Recruiting

  • Jinan Central Hospital

    Jinan, Shandong, China · Recruiting

  • Zhongshan Hospital,Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The Fifth People's Hospital of Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

  • Pudong New Area People's Hospital Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Huzhou Central Hospital

    Huzhou, Zhejiang, China · Recruiting

  • The first affiliated hospital of Ningbo university

    Ningbo, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.